ADC Therapeutics (ADCT) Net Income towards Common Stockholders (2020 - 2026)

ADC Therapeutics (ADCT) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$33.0 million the latest figure, recorded in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 14.6% year-over-year to -$33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.6 million (down 10.42% YoY) and the FY2022 annual result came in at -$152.6 million, up 33.84% from the prior year.
• Net Income towards Common Stockholders grew to -$33.0 million in Q1 2026 per ADCT's latest filing, from -$41.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ADCT reached as high as -$16.7 million in Q1 2022 and fell as low as -$64.4 million in Q2 2022.
• A 5-year average of -$42.7 million and a median of -$44.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 67.67% — and 2023, when it sank 256.68%.
• Year by year, Net Income towards Common Stockholders stood at -$18.2 million in 2022, then slumped by 149.56% to -$45.3 million in 2023, then climbed by 3.52% to -$43.7 million in 2024, then increased by 6.28% to -$41.0 million in 2025, then climbed by 19.52% to -$33.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$33.0 million, -$41.0 million, and -$56.6 million for Q1 2026, Q3 2025, and Q2 2025 respectively.